July 2, 2014 News by Charles Moore Cleveland Clinic Researchers Find iPad A Powerful Multiple Sclerosis Assessment Tool Tracking patients’ progress is a critical part of MS management, a process that can benefit from greater objective analysis. Researchers at the Cleveland Clinic have determined that tablet computers, which feature built-in technologies like accelerometers, gyroscopes, and touchscreens, when combined with appropriate software, can provide pretty good MS assessment capabilities.
June 19, 2014 News by Charles Moore Increased R&D Focus On PoNS Neuromodulation Therapy Device For People With MS; Other Neurological Conditions Newtown, Pennsylvania based Helius Medical Technologies, Inc. announced on June 6th that the company has entered into an agreement and plan of merger whereby the Company has agreed to acquire 100% of issued and outstanding common shares of Neurohabilitation Corporation (“Neuro”) of Delaware by way of a plan of…
June 16, 2014 News by Charles Moore Can Low Carb, High Fat Ketogenic Diets Improve MS And Other Neurological Disease Symptoms? Dr. Terry Wahls, a clinical professor of medicine at the University of Iowa Carver College of Medicine in Iowa City, Iowa, U.S.A., where she teaches internal medicine residents in primary care clinics, in addition to being a physician is also a multiple sclerosis (MS) patient. First diagnosed in 2000,…
June 16, 2014 News by Charles Moore Natalizumab, Other Biogen Idec MS Therapies Featured at Medical Congresses; Company Joins Sailing Sclerosis Foundation Oceans of Hope Project Biogen Idec, a U.S. biotechnology company specializing in therapies for neurological disorders, autoimmune disorders and cancer, has announced that more than 60 company-sponsored presentations highlighting key data from its extensive portfolio of marketed and investigational multiple sclerosis (MS) therapies were featured during two 2014 neurology conferences. The company…
June 12, 2014 News by Charles Moore Researchers Report Alternate Explanation Discovery Of How And Why CCSVI Treatment Works In MS Patients A new study may offer new insight on beneficial effects of “chronic cerebrospinal venous insufficiency” (CCSVI or CCVI) treatment for Multiple Sclerosis (MS) and certain other disease conditions. CCSVI is the controversial theory that blocked neck veins are a major factor in many MS cases proposed by Italian physician…
June 11, 2014 News by Charles Moore Better MS Tracking Tool Developed by Robarts Institute Scientists At University of Western Ontario A team of magnetic imaging scientists led by Dr. Ravi Menon, PhD, at the University of Western Ontario’s Robarts Research Institute have developed a better way to track the progression of Multiple Sclerosis (MS) from its very early stages. The Robarts researchers used a technique called Quantitative Susceptibility…
June 3, 2014 News by Charles Moore Another Canadian Study Finds No Link Between Blocked Neck Veins And MS Another study, in what has become a succession of Canadian studies, has failed to detect a link between blocked neck veins and multiple sclerosis proposed by Italian physician and researcher Dr. Paolo Zamboni in 2008 (a report in the Lancet noted that this hypothesis was originally posed by…
June 2, 2014 News by Charles Moore Genzyme Resubmits Multiple Sclerosis Drug Lemtrada For FDA sBLA Approval Review Cambridge, Mass. Based Genzyme, a Sanofi subsidiary, announced May 30 that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s resubmission of its supplemental Biologics License Application (sBLA) seeking approval of its proprietary drug Lemtrada (alemtuzumab) for treatment of relapsing forms of multiple sclerosis (MS).
May 30, 2014 News by Charles Moore Is Vitamin D Supplementation Effective For Fighting Multiple Sclerosis, Fibromyalgia, and Parkinson’s? Sturgeon Bay, Wisconsin chiropractor, naturopath and health blogger Dr. J.G. Moellendorf, DC, ND, LCP notes that while its been known since 1922 that Vitamin D is vital for bone health, recent research reveals its importance in many other body functions, and suggests that the “sunshine” Vitamin is, for example,…
May 28, 2014 News by Charles Moore Study Finds MS Drug Gilenya May Point To Development Of New PTSD Therapy A new study on mice published in Nature Neuroscience finds that fingolimod (Novartis brand name Gilenya) a first-in-class sphingosine-1-phosphate-receptor modulator currently used in treating persons with severe relapsing remitting MS, may also have therapeutic value in treating Post Traumatic Stress Disorder (PTSD). The Nature Neuroscience study is titled…
May 23, 2014 by Charles Moore MRI Spectroscopy May Improve Accuracy in Predicting MS Progression A new study published this week in the Journal of the American Medical Association Neurology says that predicting disease evolution is becoming essential for optimizing treatment decision-making in multiple sclerosis (MS), in which pathologic damage typically includes demyelination, neuro-axonal loss, and astrogliosis. The study, entitled “Magnetic Resonance Spectroscopy…
May 22, 2014 by Charles Moore Hematopoietic Stem Cell Transplantation: MS Breakthrough Treatment Or Another “Liberation Therapy” Disappointment Shaping Up? Multiple Sclerosis (MS) is a devastating disease for many who become afflicted with the disease’s progressive form, often in the prime of their lives, with no cure and when the effectiveness of established MS treatment is so often disappointing. Discouragement can lead to pinning premature hope on unproven therapies…
May 16, 2014 by Charles Moore Researchers Report Encouraging Results in Mouse Model MS Stem Cell Therapy Research Scientists at the Scripps Research Institute (TSRI), the University of California (UC), Irvine and The University of Utah report that mice crippled by an autoimmune disease similar to multiple sclerosis (MS) regained the ability to walk and run after a team of researchers implanted human stem cells…
May 7, 2014 News by Charles Moore Genzyme Enters Multi-Year MS Research Collaboration with Cleveland Clinic’s Academic Medical Center Cambridge, Massachusetts based biotech firm Genzyme has formed a new research collaboration with Cleveland Clinic of Cleveland, Ohio with a focus on developing new therapeutic approaches to the treatment of Multiple Sclerosis (MS). More than 2.3 million people worldwide have been diagnosed with MS, including what is believed…
May 7, 2014 News by Charles Moore MS, Other Autoimmune Diseases, May Be Vulnerable To New Drug Strategy Identified In UCSF/Harvard Genome Study New classes of pharmaceutical agents tailored to fight autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis and psoriasis, may be identified more effectively by adding genome analysis to standard drug screening, according to results of a new study by a collaborative research team led by UC San Francisco and…
May 1, 2014 News by Charles Moore Debate Over Medical Marijuana For MS And Other Diseases Heats Up Steve Pepple / Shutterstock.com The 2012 state ballot approvals of marijuana legalization in Colorado and Washington has been a catalyst for stirring the pot, so to speak, on a wide range of issues and nuances related to the herb — not least marijuana’s clinical use as a…
April 21, 2014 by Charles Moore Supreme Court Denies Injunction Request To Block Release Of Generic MS Drug, But Patent Fight Not Over Yet Petah Tikvah Israel-based Teva Pharmaceutical Industries Ltd. has suffered a setback in its fight to forestall release of generic competitors for its proprietary Copaxone Multiple Sclerosis drug. However, the company is expressing optimism that potential for recovery of Patent Infringement Damages may dissuade aspirant generic competitors from proceeding until a…
